Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €54.80 EUR
Change Today -0.354 / -0.64%
Volume 61.5K
As of 3:35 PM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

gerresheimer ag (GXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/14/15 - €57.80
52 Week Low
10/16/14 - €41.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GERRESHEIMER AG (GXI)

Related News

No related news articles were found.

gerresheimer ag (GXI) Related Businessweek News

No Related Businessweek News Found

gerresheimer ag (GXI) Details

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates in three divisions: Plastics and Devices, Primary Packaging Glass, and Life Science Research. The Plastics and Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. This division also provides containers for the delivery of tablets and powder, liquid dosage, ophthalmic and rhinological applications, and parenteral packaging applications. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials and syringe barrels, cartridges, syrup and dropper bottles, tablet jars, wide-neck jars and injections, and infusion and transfusion bottles; and flacons and pots for fragrances, deodorants, care and decorative cosmetics, etc., as well as specialty containers for spirits and food. The Life Science Research division produces reusable laboratory glassware for the research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders; and disposable laboratory products, including culture tubes, pipettes, chromatography vials, and other specialty laboratory glassware. Gerresheimer AG was founded in 1864 and is headquartered in Düsseldorf, Germany.

11,050 Employees
Last Reported Date: 04/14/15
Founded in 1864

gerresheimer ag (GXI) Top Compensated Officers

Chairman of the Management Board and Chief Ex...
Total Annual Compensation: €1.1M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €855.0K
Member of the Management Board
Total Annual Compensation: €805.0K
Compensation as of Fiscal Year 2014.

gerresheimer ag (GXI) Key Developments

Corning Incorporated Agrees to Form a Joint Venture with Gerresheimer AG

Corning Incorporated has agreed to form a joint venture with Gerresheimer AG to accelerate pharmaceutical glass packaging products. Under the transaction, Corning will hold a 75% stake in the joint venture, while the remaining 25% stake will be held by Gerresheimer. In addition, Corning has agreed to acquire the borosilicate glass tubing business of Gerresheimer for approximately EUR 196 million on a debt-free basis. Corning and Gerresheimer have also entered into a 10-year-supply agreement for borosilicate glass tubes. The joint venture will allow Gerresheimer to expand its product portfolio of tubular pharmaceutical packaging products.

Gerresheimer AG Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-17-2015

Gerresheimer AG Presents at Deutsche Bank dbAccess German, Swiss & Austrian Conference 2015, Jun-17-2015 . Venue: Berlin, Germany.

Gerresheimer AG Reports Earnings Results for the First Quarter Ended February 28, 2015; Provides Earnings Guidance for the Financial Year 2015 and for 2016 to 2018

Gerresheimer AG reported earnings results for the first quarter ended February 28, 2015. For the quarter, the company reported net income attributable to equity holders of the parent of EUR 11.02 million, or EUR 0.35 per share, compared to EUR 8.95 million, or EUR 0.29 per share, for the same quarter ended February 28, 2014. Revenues were EUR 301.76 million, compared to EUR 297.49 million for the same quarter ended February 28, 2014. Net income before income taxes was EUR 17.45 million, compared to EUR 14.14 million for the same quarter ended February 28, 2014. The company achieved a significantly larger increase in adjusted EBITDA, which was up 7.2% from EUR 47.6 million in the prior-year quarter to EUR 51.0 million. At constant exchange rates, adjusted EBITDA stood at EUR 50.2 million. The company incurred capital expenditure of EUR 13.9 million in the first quarter of 2015, compared with EUR 21.7 million in the prior-year quarter. Major part of capital expenditure was accounted for by glass primary packaging plants. The focus was on capital expenditure on vial and cartridge machinery as well as on routine furnace overhauls. For financial year 2015, the company expects organic revenue growth of between 1% and 3%. This corresponds to a revenue corridor of some EUR 1,300 million to EUR 1,330 million. The company anticipates an increase in adjusted EBITDA in a target corridor of between EUR 255 million and EUR 265 million. Capital expenditure in financial year 2015 will amount to around 9% and 10% of revenues at constant exchange rates. For financial years 2016 to 2018, the company expects annual organic revenue growth of 4% to 6% on average. For the adjusted EBITDA margin, the company is aiming at a target of 21% in 2018. To attain these targets, an annual investment volume in the range of 9% to 10% of revenue at constant exchange rates will be required.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GXI:GR €54.80 EUR -0.354

GXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Carclo PLC 146.25 GBp -1.25
Consort Medical PLC 906.00 GBp -2.00
Vitro SAB de CV $47.53 MXN +0.46
West Pharmaceutical Services Inc $57.55 USD -0.77
Zignago Vetro SpA €5.36 EUR +0.025
View Industry Companies

Industry Analysis


Industry Average

Valuation GXI Industry Range
Price/Earnings 25.1x
Price/Sales 1.3x
Price/Book 3.1x
Price/Cash Flow 25.1x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERRESHEIMER AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at